Business
IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the American Society of Breast Surgeons (ASBrS) is in the final stage of updating its "Resource Guide on Transcutaneous and Percutaneous Treatment of Benign and Malignant Tumors of the Breast" which should include cryoablation for the local treatment of breast ca
About this update from Icecure Medical Ltd.
[{"type":"text","content":"ASBrS's updated "Resource Guide on the Use of Transcutaneous and Percutaneous Ablation for the Treatment of Benign and Malignant Tumors of the Breast" is pending finalization following the end of its open comment period on January 23, 2026","length":253,"tagName":"p","attribs":{}},{"type":"text","content":"Inclusion of cryoablation in medical society guidelines is expected to result in more breast surgeons recommending cryoablation to appropriate patients","length":151,"tagName":"p","attribs":{}},{"type":"text","content":"Finalized updated guidelines are expected to mark a major step towards widespread adoption of cryoablation in the United States and a new standard of care in breast cancer by offering a minimally invasive procedure that destroys tumors by freezing, without surgery","length":269,"tagName":"p","attribs":{}},{"type":"text","content":"CAESAREA, Israel, Jan. 28, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the American Society of Breast Surgeons (ASBrS) is in the final stage of updating its "Resource Guide on Transcutaneous and Percutaneous Treatment of Benign and Malignant Tumors of the Breast" which should include cryoablation for the local treatment of breast cancer in patients aged ≥70 years, with biologically low-risk tumors measuring ≤1.5 cm, who are treated with adjuvant endocrine therapy, including patients who are not suitable candidates for surgery. The current draft of the proposed recommendation aligns with the U.S. Food and Drug Administration's ("FDA") marketing authorization granted in October 2025 for the use of cryoablation in the treatment of breast cancer. The proposed update to the ASBrS guidelines also recommends cryoablation for small benign tumors of the breast (fibroadenoma).","length":1152,"tagName":"p"},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"image","alt":"IceCure Medical Logo","displaySize":"","headline":null,"caption":"IceCure Medical Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com...